We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The efficacy and safety of Apatinib in the treatment of advanced non-small cell lung cancer: A retrospective trial.
- Authors
Jijin Wang; Di Huang; Wenjing Yang; Qingxu Song; Yibin Jia; Pengxiang Chen; Yufeng Cheng
- Abstract
Background: As a potent inhibitor of the vascular endothelial growth factor (VEGF) signaling pathway, Apatinib has been used in antitumor treatment for some time. The study aimed to research the therapeutic effects and toxicity of Apatinib in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: We retrospectively analyzed 128 NSCLC patients treated with Apatinib in Qilu Hospital of Shandong University. Response Evaluation Criteria in Solid Tumors (RECIST) criteria was adopted to evaluate the treatment effect, and Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 was conducted to determine the Adverse Events (AEs). Cox proportional hazard model and Kaplan-Meier function were applied to evaluate the progression-free survival (PFS) and overall survival (OS). Results: Among 128 NSCLC patients, partial response (PR) were observed in 15 patients, stable disease (SD) in 66 patients and progressive disease (PD) in 47 patients. The objective response rate (ORR) and disease control rate (DCR) accounted for 11.7% and 63.3% respectively. The median PFS (mPFS) and median OS (mOS) were 4.4 months and 17.2 months. Common side effects of Apatinib were hypertension (n=48), proteinuria (n=35), and hand-foot syndrome (HFS) (n=30), all of the side effects were controllable. No significant difference was observed in efficacy and AEs between the higher dose group (Apatinib>500mg/d) and the lower dose group (Apatinib=500mg/d). Conclusions: The study suggested that Apatinib with a lower dose (=500mg/d) has good efficacy and safety in the treatment of advanced NSCLC after first line chemotherapy.
- Subjects
NON-small-cell lung carcinoma; APATINIB; VASCULAR endothelial growth factor antagonists; PROPORTIONAL hazards models; HAND-foot syndrome
- Publication
Frontiers in Oncology, 2022, Vol 12, p01
- ISSN
2234-943X
- Publication type
Article
- DOI
10.3389/fonc.2022.1030798